Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide
combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.